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SUMMARY 
The functional significance of hypothalams-pituitary axis as a neurohormonal link between endocrine 
glands and target organs is well established. It has also been demonstrated that three hormones of anterior pituit-
ary viz. Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with 
Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Radio immune assay 
technique was employed in estimation. Significantly low PRL level was found in majority of cases. However there 
was no significant corelation with effects of therapy or with L-DOPA administration. Similarly LH level was also 
found low indicatiqg increased DA activity but the low level persisted even after therapy. GH level did not show 
any alteration in the patients, even when compared to different blood sugar levels and L-DOPA administration. 
Introduction 
The relationship between endocrine 
functions and psychiatric illnesses had at-
tracted interest of both endocrinologists 
and psychiatrists for a long time. In the 
past, a number of psychiatric conditions 
were attributed empirically to endocrine 
abnormalities. The functional significance 
of hypothalmo-pituitary axis as a 
neurohormonal link between 
hypothalamus, anterior pituitary gland 
and target organs was demonstrated long 
back (Green et al. 1947). Recent advances 
in endocrine research techniques have 
helped substantially in gaining insight into 
possible biological etiology of so called 
functional psychiatric illnesses. It is known 
that endocrine functions are primarily con-
trolled by the hypothalamus which is an in-
tegral part of the limbic system. The latter 
is implicated today as the prime seat for 
mental functioning and any abnormality in 
it is likely to produce psychiatric abnor-
malities. Neuro-endocrine evaluation is 
thus a rational probe into the functions of 
the limbic system. 
It has been demonstrated by animal 
experiments as well as human studies that 
out of the six hormones of the anterior 
pituitary, at least three of them have defi-
nite link with dopamine (DA). They are: 
Prolactin (PRL), Lutenising hormone 
(LH), and Growth hormone (GH). Pro-
lactin has inverse relation with dopaminer-
gic activity as evidenced by its rise with DA 
block by antipsychotic drugs. DA is the re-
lease inhibiting factor for LH and the DA 
agonists stimulate the release of GH (Shaw 
et al. 82). Dopamine hypothesis still holds 
the pride of place in the possible etiological 
hypothesis of schizophrenia. The increased 
dopaminergic activity ought to reflect in the 
circulating levels of the hormones with 
which it is lined. Thus finding the levels of 
these hormones viz. prolactin, LH and GH 
would indicate the degree of dopaminergic 
activity in a schizophrenic. With this as-
sumption the present project was planned. 
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Material and Methods 
The work was carried out in two large 
service hospitals, during 1982-84. Fresh 
patients of schizophrenia who met with the 
criteria (as below) of selection were en-
tered into the study sample. Criteria were; 
(a) General : 1. They must be free from 
any drug for at least two weeks 2. No evi-
dence of any physical illness, particularly 
pointing to endocrinopathy 3. They must 
be willing and cooperative enough to un-
dergo various tests. 
(b) Diagnosis: 1. Patients showing a 
number of Schneider's first order of 
symptoms or a combination with other 
characteristic symptoms were only in-
cluded. 2. Two senior psychiatrists (one of 
whom being the author) must agree on the 
diagnosis. 3. Psychological tests viz. 
Rorschach's test and MMPI also corrobo-
rated the diagnosis. In all. eighty four pa-
tients satisfied the above criteria and con-
stituted the study sample. Forty age 
matched healthy individuals, screened 
thoroughly to exclude any physical illness, 
were picked up from staff of the hospitals. 
Age range of the patient sample was 22 to 
46 years, mean being 32. 45 while that of 
control the mean was 30, range being 21 to 
45 years. 
All the subjects were in-patients, ad-
mitted fresh. Seven days passed before the 
study started and during this period, diag-
nostic and routine investigations were car-
ried out. The schedule for the endocrine 
analysis was as follows:-
Day 8: (i) Fasting blood was collected for 
estimation of GH, LH, PRL and blood 
sugar, (ii) Glucose tolerance Test (GIT) 
was performed using 100 gms glucose load. 
Blood samples were taken after 30,60,90 
and 120 minutes for estimation of sugar as 
well as GH. Blood sugar and GTT were 
done as they are known to influence GH, 
hypoglycemia being a stimulating factor. 
Day 11:2 tablets of L-DOPA were given 
to each patient and their blood was col-
lected at 0,90 and 120 minutes. This was 
done to see further the effects of en-
chanced DA activity. 
Antipsychotic drugs or convulsive 
therapy was not given before twelth day of 
admission. The schedule of the endocrine 
tests was repeated again after (i) three 
weeks of starting therapy (ii) when clinical 
recovery was apparent at about twelve to 
sixteen weeks. For the control sample, the 
tests were not repeated. 
Radio Immune Assay Technique 
(RIA) was employed for the analysis of 
hormones. Estimation of PRL, GH and 
LH were done by the method of Berson 
and Yalow (1964). Standards for all the 
hormones were made available by the 
courtesy of the National Institute of 
Health, USA. The labelled hormones for 
RIA were prepared in our own laboratory 
by the method of Greenwood and Hunter 
(1963). 
Results 
Table 1 
(Levels of PRL, LH and HGH) 
Subjects 
Control 
Mean& 
SE1 
Mean& 
SEN + 
PRL 
ng/ml 
13.09 
0.95 
LH 
IU/L 
12.10 
0.92 
HGH 
ng/ml 
5.83 
0.59 
Patients Be-
fore therapy 
During 
therapy 
After 
recovery 
Mean& 
SEM± 
Mean& 
SEM± 
Mean& 
SEM± 
11.88* 
0.69 
12.61 
0.91 
12.80 
0.16 
6.05** 
0.60 
5.86** 
0.53 
5.69** 
0.42 
5.90 
0.60 
5.75 
0.58 
6.04 
0.61 
* Indicate significance at 5.0% p 0.05 
** Indicate significance at 1.0% p 1.01 S B CHATTERJEE 
Table 2 
(GTT and simultaneous HGH Level) 
Subject 
Control 
Patients 
Before 
therapy 
During 
therapy 
After 
recovery 
Mean& 
SEM + 
Mean& 
SEM± 
Mean& 
SEM + 
Mean& 
SEM + 
Mean& 
SEM± 
F 
82.80 
2.68 
73.33 
3.33 
79.33 
2.53 
82.22 
3.16 
GIT 
30 
95.70 
2.70 
108.33 
12.43 
104.89 
5.58 
105.00 
5.83 
60 
101.05 
3.07 
105.55 
6.70 
102.33 
5.44 
105.90 
6.03 
90 
90.60 
6.94 
96.11 
7.S9 
85.22 
4.96 
92.78 
6.28 
120 
77.00 
2.21 
90.00 
1240 
78.50 
3.89 
80.00 
5.66 
F 
5.83 
0.59 
5.90 
0.60 
5.75 
0.58 
6.04 
0.61 
HGH 
30 
4.81 
0.32 
6.63 
0.29 
5.81 
0.18 
5.44 
0.24 
60 
4.31 
0.29 
5.45 
0.27 
5.40 
0.28 
4.80 
0.20 
90 
4.89 
0.32 
5.82 
0.15 
6.05 
0.30 
5.33 
0.20 
120 
5.66 
0.29 
6.61 
0.17 
6.73 
0.26 
6.16 
0.18 
Table 3 
(L-DOPA Effects on HGH and PRL) 
Subject Mean& 
SEM+ F 
Control Mean & 5.83 
SEM + 0.59 
HGH ng/ml PRL ng/ml 
90 120 F 90 120 
6.08 5.87 13.09 13.16 12.49 
0.35 0.27 0.95 1.07 0.91 
Patients SEM ± 5.90 
before SEM + 0.60 
therapy 
During Mean & 5.75 
therapy SEM ± 0.58 
After Mean & 6.04 
recovery SEM ± 0.61 
5.00 
0.14 
5.93 
0.60 
5.66 
0.94 
5.68 
0.57 
5.63 
0.56 
5.91 
0.57 
* Indicate significance at 5.0% leve 
11.88* 
0.69 
12.61 
0.61 
12.80 
0.16 
9.45* 
0.68 
9.32* 
0.60 
9.80* 
0.63 
1 p < 0.05 
Discussion 
9.56* 
0.61 
10.11* 
0.72 
10.80* 
0.73 
Dopamine hypothesis is mainly de-
pendent on two observations viz. (a) effect 
of DA agonists, mainly amphetamine, in 
producing and/or aggravating psychotic 
picture (b) antipsychotic drugs produce 
their effect by DA blockade. However, es-
timation of DA level of serum in vivo is not 
a certain method and hence estimation of 
prolactin (PRL) is utilised to indicate DA 
activity by virtue of its inverse relationship 
with DA. Today it is universally acknow-
ledged that PRL response reliably reflects 
the DA blocking properties of neurolep-
tics (Kolkowska et al. 1975 and Wilson et 
al. 1975). For the last two decades, PRL is 
being used as a DA marker, rise of PRL 
level indicating positive response to 
therapy. While quite a few workers have 
found low level of PRL in schizophrenics, 
Gruen et al. (1978) did not find so; on the 
contrary they found either normal or 
slightly elevated PRL level in unmedicated 
patients. Our finding of significant low 
level of PRL in a large number of patients 
before therapy support the findings of 
majority of workers. Strangely, the mean 
PRL level did not show any significant rise 
with therapy, for which we do not find any 
ready explanation. It could be that dosage 
of neuroleptics was much lower than what 
is prescribed in the western countries. We 
normally do not have to go beyond 300 mg 
of Chlorpromazine or its equivalent, un-
less the condition of a particular patient 
demands so. However about the fourth of 
the patients did show significant rise 
though this is not reflected in the mean 
reading because three fourth of them did 
not show any significant rise. Another ob-
servation was the effect of L-DOPA ad-
ministration, when reduction of PRL level 
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This would perhaps indicate the DA sen-
sitivity of schizophrenics. Attempts to cor-
relate PRL response with the activity of 
antipsychotic drugs and the clinical re-
sponse remain still controversial. Meltzer 
and Fang (1976) had reported significant 
correlation while Gruen et al. (1978) were 
unable to find any such. In our study too 
there was no correlation because though 
clinical recovery was apparent in all the pa-
tients, PRL rise was not significant. 
Of the three principal subgroups of 
DA distribution, viz. substantia nigra, 
nucleus accumbens and the arcuate nuc-
leus of hypothalamus, the last group is be-
lieved to be responsible for the production 
of LH releasing factor (LHRF), which is a 
peptide, while LH release inhibiting factor 
has been identified as Dopamine. Seroto-
nin stimulates production of PRL which in-
turn depresses LH level either directly or 
by supressing LHRH secretion (Pilotte 
and Porter 1981). Recently it has been 
shown that LH is also under control of a 
dopaminergic pathway and will be influ-
enced by DA blocking drugs (Shaw et al. 
1982). It has also been shown experimen-
tally that LH does influence animal's be-
haviour also. If simple overactivity of DA 
system is the cause of schizophrenia, then 
we would expect a diminution of LH level 
in plasma. Our observations point out to 
this fact (table 1), where low level of LH 
was highly significant. However, the low 
level persisted even after therapy and also 
after apparent clinical tecovery, when suf-
ficient DA block presumably could have 
been achieved. This cannot be explained 
so simply. Possibly the same reason as in 
the case of PRL, viz. inadequate dosage of 
neuroleptics could have made the differ-
ence. 
Growth hormone (GH) like other 
hormones of anterior pituitary, is under in-
fluence of many stimulatory and inhibitory 
mechanisms. As per present knowledge, it 
is stimulated by 5HT, dopamine and 
catechol receptors while inhibited by 
somatostatin and catechol receptors (Shaw 
et al. 1982). Hypoglycaemia is also known 
to stimulate its production and aberrations 
of GH production has been noted in a 
number of conditions like anorexia ner-
vosa, post menopausal women etc. There 
are quite a few studies linking GH with 
schizophrenia; unfortunately the results 
are confusing. Syvalahti and Pekkarinen 
(1977) studied GH response to sleep in ten 
chronic schizophrenics and compared 
them with five epileptics. They did not find 
any difference. Day time agonist study by 
0.75 mg apomorphine administration was 
done by Ettigi et al. (1976) in seventeen 
chronic schizophrenic and they compared 
them with twelve controls. Schizophrenics 
showed significantly low GH response. 
Tamminga et al. (1977), used L-DOPA as 
agonist in nine chronic schizophrenics and 
compared with twelve controls. They also 
noticed blunted peak GH response. How-
ever, Retrosen et al. (1979) found a 
bimodal distribution (some having high 
and some of them low) in GH response to 
apomorphine while Meltzer et al. (1981) 
found GH response higher in schizop-
hrenics. In our patients GH level did not 
show any significant increase from normal 
control (table 1); thus influence of DA 
overactivity if any in them, did not mate-
rially affect the GH production. With vary-
ing glucose levels during GTT, GH did not 
show any significant variation either and 
L-DOPA also similarly did not affect its 
plasma level (tables 2 & 3). Patient popula-
tion of present study were all acute cases in 
contrast to chronic cases studied by others. 
The results of this study of the three 
dopamine related hormones do not give a 
clear picture of a simple increased 
dopamineric activity. Some areas (prolac-
tin and LH) are positive while GH is not. It 
appears that in the light of the recent S B CHATTERJEE  11 
thinking of dividing the schizophrenics 
into larger and normal ventricular size 
groups and the positive/negative 
symptoms, a hormone study needs to be 
supplemented with clinical scrutiny as well 
as CT scan. 
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